Zobrazeno 1 - 10
of 27
pro vyhledávání: '"Anthony J Jaslowski"'
Autor:
Ciara C O Sullivan, Jun He, Vera J Suman, Krishna R Kalari, Roberto A Leon-Ferre, Jose C Villasboas-Bisneto, Pratima Chalasani, Demet Gokalp Yasar, Daniel M Anderson, Philip J Stella, Anthony J Jaslowski, Susan H Tannenbaum, Angela Saverimuthu, Donald Northfelt, Alvaro Moreno-Aspitia, Jodi M Carter, Minetta C Liu, Liewei Wang, Zhenkun Lou, Matthew P Goetz
Publikováno v:
Cancer Research. 82:OT2-19
Background: Although major advances have been made in the treatment of HER2+ metastatic breast cancer (MBC), the goal of care remains largely palliative, therefore better treatments are needed. Given encouraging preclinical and clinical data, the com
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::9e09d8da5752882f1223dbb4dfd1bd68
https://doi.org/10.1158/1538-7445.sabcs21-ot2-19-05
https://doi.org/10.1158/1538-7445.sabcs21-ot2-19-05
Autor:
Timothy M. Kuzel, Gary I. Cohen, Ahmad A. Tarhini, Christopher D. Lao, Sandra J. Lee, Darell R. Borger, Andrew L. Pecora, Henry B. Koon, John M. Kirkwood, Krista M. Rubin, Mario M. Leitao, Kim Margolin, Kevin Kalinsky, Anthony J. Jaslowski, Anthony J. Iafrarte, Donald P. Lawrence
Publikováno v:
Cancer. 123:2688-2697
BACKGROUND KIT-directed tyrosine kinase inhibitors such as imatinib have demonstrated benefits in KIT-mutant (KIT+) mucosal, acral, vulvovaginal, and chronically sun-damaged (CSD) melanoma. Dasatinib has superior preclinical activity in comparison wi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f597e1c0ed88b4d331927f46af85ea8e
https://doi.org/10.1002/cncr.30663
https://doi.org/10.1002/cncr.30663
Autor:
Anthony J. Jaslowski, Christie J. Lau, Stephen L. Graziano, Maria Q. Baggstrom, Cloud P. Paweletz, Lin Gu, Gregory J. Gerstner, Erin M. Bertino, Everett E. Vokes, Thomas E. Stinchcombe, Pasi A. Jänne, James D. Bearden, Jared Weiss, Xiaofei Wang, Lyudmila Bazhenova
Publikováno v:
JAMA Oncol
IMPORTANCE: Erlotinib is a standard first-line therapy for patients with epidermal growth factor receptor (EGFR)–mutant non–small cell lung cancer (NSCLC). Median progression-free survival (PFS) with erlotinib is approximately 10 months. OBJECTIV
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a32eee33b82ec223fb8b6ba5354ac3a5
https://pubmed.ncbi.nlm.nih.gov/31393548
https://pubmed.ncbi.nlm.nih.gov/31393548
Autor:
Amy C. Vander Woude, Eva Culakova, Nikesha Gilmore, Kah Poh Loh, Amber S. Kleckner, Michelle C. Janelsins, Charles E. Heckler, Sara Hardy, Alison Conlin, Anthony J. Jaslowski, Huiwen Xu, Karen M. Mustian, Po-Ju Lin, Richard F. Dunne, Ian R. Kleckner, Luke J. Peppone
Publikováno v:
Journal of Clinical Oncology. 39:12017-12017
12017 Background: Patients commonly experience impaired sleep throughout cancer treatment and for years into survivorship. Impaired sleep may mediate other cancer-related symptoms and can lead to the inability to complete daily activities and lower q
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b7ceb9b246eec4dcbf16950969baaf3c
https://doi.org/10.1200/jco.2021.39.15_suppl.12017
https://doi.org/10.1200/jco.2021.39.15_suppl.12017
Autor:
Erik Asmus, Claudine Isaacs, Donald B. Wender, Lauren J. Rogak, Ethan Basch, Bret Edward Buckley Friday, DeQuincy Andrew Lewis, Thomas H. Openshaw, Gini F. Fleming, Alvaro Moreno-Aspitia, Amylou C. Dueck, Minetta C. Liu, Kendrith M. Rowland, Nguyet A. Le-Lindqwister, Alan P. Lyss, Ashley Frith, John T. Cole, Anthony J. Jaslowski, Douglas Weckstein, David W. Hillman
Publikováno v:
Journal of Clinical Oncology. 38:1016-1016
1016 Background: The ph III EMBRACE trial of E vs physician’s choice of tx led to FDA approval of E as ≥3rd-line tx for MBC pts with prior exposure to anthracyclines/taxanes. The ph III BOLD 301 trial of E vs capecitabine in advanced BC treated w
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::e71bf43f76db7bbccf5c0151772ab159
https://doi.org/10.1200/jco.2020.38.15_suppl.1016
https://doi.org/10.1200/jco.2020.38.15_suppl.1016
Autor:
Kah Poh Loh, Michelle C. Janelsins, Amber S. Kleckner, Huiwen Xu, Anthony J. Jaslowski, Luke J. Peppone, Javier Bautista, Alison Conlin, Po-Ju Lin, Kim Ong Gococo, Supriya G. Mohile, Nikesha Gilmore, Eva Culakova, Karen M. Mustian, Richard F. Dunne, Ian R. Kleckner
Publikováno v:
Journal of Clinical Oncology. 38:12005-12005
12005 Background: Insomnia, a prevalent and troublesome side effect experienced by cancer survivors, significantly impairs recovery and survival. We conducted a nationwide, multicenter, phase III, blinded, randomized controlled trial testing whether
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::d4daedc1b3c8acadc55e4a91f11ea7cd
https://doi.org/10.1200/jco.2020.38.15_suppl.12005
https://doi.org/10.1200/jco.2020.38.15_suppl.12005
Autor:
C. S. Adonizio, Charles L. Loprinzi, Preston D. Steen, Jeff A. Sloan, Kendrith M. Rowland, Dennis F. Moore, Anthony J. Jaslowski, Nguyet A. Le-Lindqwister, Aminah Jatoi, Pamela J. Atherton
Background Multiple pilot studies, including one in colorectal cancer patients, suggest that creatine, an amino acid derivative, augments muscle, improves strength, and thereby could palliate the cancer anorexia/weight loss syndrome. Patients and met
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4e9d607498c56fcaa14aad44946c5064
https://europepmc.org/articles/PMC5808669/
https://europepmc.org/articles/PMC5808669/
Autor:
Kevin, Kalinsky, Sandra, Lee, Krista M, Rubin, Donald P, Lawrence, Anthony J, Iafrarte, Darell R, Borger, Kim A, Margolin, Mario M, Leitao, Ahmad A, Tarhini, Henry B, Koon, Andrew L, Pecora, Anthony J, Jaslowski, Gary I, Cohen, Timothy M, Kuzel, Christopher D, Lao, John M, Kirkwood
Publikováno v:
Cancer. 123(14)
KIT-directed tyrosine kinase inhibitors such as imatinib have demonstrated benefits in KIT-mutant (KIT+) mucosal, acral, vulvovaginal, and chronically sun-damaged (CSD) melanoma. Dasatinib has superior preclinical activity in comparison with other ty
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::293db0c531584e69264ceca89aa6dca6
https://pubmed.ncbi.nlm.nih.gov/28334439
https://pubmed.ncbi.nlm.nih.gov/28334439
Autor:
Svetomir N. Markovic, Peter A. Cohen, Matthew L. Kosel, Robert R. McWilliams, Francois J. Geoffroy, Thomas Amatruda, Lisa A. Kottschade, Howard M. Gross, Vera J. Suman, Domingo G. Perez, Judith S. Kaur, Anthony J. Jaslowski
Publikováno v:
Cancer. 119:586-592
BACKGROUND: Increasing evidence shows chemotherapy in combination with vascular endothelial growth factor (VEGF) inhibition is a clinically active therapy for patients with metastatic melanoma (MM). METHODS: A phase 2 trial was conducted in chemother
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0056c71d1b19953f9feea556e06db848
https://doi.org/10.1002/cncr.27760
https://doi.org/10.1002/cncr.27760
Autor:
Shaker R. Dakhil, Jeff A. Sloan, Charles L. Loprinzi, Kelli N. Burger, Daniel H. Lachance, Brandi N. Reeves, Anthony J. Jaslowski, Sherry L. Wolf, Gamini S. Soori, Arif H. Kamal, Joseph Kelaghan, Nguyet A. Le-Lindqwister, Paul J. Novotny
Publikováno v:
Cancer. 118:5171-5178
BACKGROUND: Paclitaxel causes an acute pain syndrome (P-APS), occurring within days after each dose and usually abating within days. Paclitaxel also causes a more classic peripheral neuropathy, which steadily increases in severity with increasing pac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc7c987ccf72e7b5d5072e70c9decbae
https://doi.org/10.1002/cncr.27489
https://doi.org/10.1002/cncr.27489